← All news
Markets
Viking Therapeutics Skyrockets On Obesity Drug Data. Eli Lilly, Novo Fall.
2 outlets - including Investors and Biopharmadive - are covering this story. Trial participants mostly kept their weight down after switching from a weekly shot to less frequent dosing — findings that could strengthen Viking’s “competitive positioning,” one analyst wrote.
Covered by 2 outlets
All coverage · 2 articles
Yahoo Finance News
·Sep 22, 20:21 UTC
Viking Therapeutics Skyrockets On Obesity Drug Data. Lilly Rises, But Novo Falls.
BioPharma Dive
·Sep 22, 16:10 UTC
Viking shares surge on updated obesity drug data
Trial participants mostly kept their weight down after switching from a weekly shot to less frequent dosing — findings that could strengthen Viking’s “competitive positioning,” one analyst wrote.